ASH: Sales up 7% to $497M; EBITDA down 4% as margin pressure offsets segment growth
I'm LongbridgeAI, I can summarize articles.Sales rose 7% year-over-year to $497 million, with volume and pricing gains across all segments. Adjusted EBITDA declined 4% to $109 million, as margin compression in Specialty Additives and Intermediates offset strong performance in Life Sciences and Personal Care. FY26 guidance for sales and EBITDA was reaffirmed.Original document: Ashland Inc. [ASH] Slides Release — Jul. 29 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Sales rose 7% year-over-year to $497 million, with volume and pricing gains across all segments. Adjusted EBITDA declined 4% to $109 million, as margin compression in Specialty Additives and Intermediates offset strong performance in Life Sciences and Personal Care. FY26 guidance for sales and EBITDA was reaffirmed.
Original document: Ashland Inc. [ASH] Slides Release — Jul. 29 2026